HRP20181462T1 - Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva - Google Patents

Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva

Info

Publication number
HRP20181462T1
HRP20181462T1 HRP20181462TT HRP20181462T HRP20181462T1 HR P20181462 T1 HRP20181462 T1 HR P20181462T1 HR P20181462T T HRP20181462T T HR P20181462TT HR P20181462 T HRP20181462 T HR P20181462T HR P20181462 T1 HRP20181462 T1 HR P20181462T1
Authority
HR
Croatia
Prior art keywords
regorafenib
treatment
combination
colon cancer
acetylsalicylic acid
Prior art date
Application number
HRP20181462TT
Other languages
English (en)
Croatian (hr)
Inventor
Olaf Weber
Karl Ziegelbauer
Original Assignee
Bayer Pharma Aktiengesellschaft
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20181462(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma Aktiengesellschaft, Bayer Ag filed Critical Bayer Pharma Aktiengesellschaft
Publication of HRP20181462T1 publication Critical patent/HRP20181462T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20181462TT 2012-09-25 2013-09-23 Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva HRP20181462T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12185852 2012-09-25
PCT/EP2013/069735 WO2014048881A1 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating cancer
EP13770659.4A EP2900269B1 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating colorectal cancer

Publications (1)

Publication Number Publication Date
HRP20181462T1 true HRP20181462T1 (hr) 2018-11-02

Family

ID=46963566

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181462TT HRP20181462T1 (hr) 2012-09-25 2013-09-23 Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva

Country Status (29)

Country Link
US (1) US10898500B2 (enExample)
EP (1) EP2900269B1 (enExample)
JP (1) JP6294888B2 (enExample)
KR (1) KR102210575B1 (enExample)
CN (1) CN104994876A (enExample)
AU (1) AU2013322854B2 (enExample)
BR (1) BR112015006686B1 (enExample)
CA (1) CA2885688C (enExample)
CL (1) CL2015000744A1 (enExample)
CY (1) CY1120939T1 (enExample)
DK (1) DK2900269T3 (enExample)
EA (1) EA032023B1 (enExample)
ES (1) ES2687985T3 (enExample)
HK (1) HK1214169A1 (enExample)
HR (1) HRP20181462T1 (enExample)
HU (1) HUE039878T2 (enExample)
IL (1) IL237690B (enExample)
LT (1) LT2900269T (enExample)
MX (1) MX357035B (enExample)
MY (1) MY183969A (enExample)
NZ (1) NZ705860A (enExample)
PH (1) PH12015500587A1 (enExample)
PL (1) PL2900269T3 (enExample)
PT (1) PT2900269T (enExample)
RS (1) RS57875B1 (enExample)
SG (2) SG10201702356VA (enExample)
SI (1) SI2900269T1 (enExample)
WO (1) WO2014048881A1 (enExample)
ZA (1) ZA201502840B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2861566T1 (sl) 2012-06-13 2017-03-31 F. Hoffmann-La Roche Ag Novi diazaspirocikloalkan in azaspirocikloalkan
PL2900669T3 (pl) 2012-09-25 2020-01-31 F. Hoffmann-La Roche Ag Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
AU2014356583B2 (en) 2013-11-26 2019-02-28 F. Hoffmann-La Roche Ag New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl
CR20160418A (es) 2014-03-26 2016-11-07 Hoffmann La Roche Nuevos compuestos biciclicos de 7 eslabones
MA50635A (fr) 2014-03-26 2020-08-12 Hoffmann La Roche Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique
CN104829523B (zh) * 2014-04-30 2017-10-31 药源药物化学(上海)有限公司 瑞戈非尼盐及其晶型、制备方法
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
EP3344619B1 (en) 2015-09-04 2020-10-28 H. Hoffnabb-La Roche Ag Phenoxymethyl derivatives
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
BR112018006080A2 (pt) 2015-09-24 2018-10-09 F. Hoffmann-La Roche Ag novos compostos bicíclicos como inibidores de dupla ação de atx/ca
AU2016328437A1 (en) 2015-09-24 2018-01-25 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
WO2017050747A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
LT3474858T (lt) * 2016-06-28 2021-12-27 Asamedic As Dviejų komponentų kompozicija, apimanti acetilsalicilo rūgštį
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
PT3630112T (pt) * 2017-06-02 2024-04-23 Bayer Healthcare Llc Combinação de regorafenib e nivolumab para tratamento de cancro
EP3501522A1 (en) 2017-12-22 2019-06-26 Asamedic AS Compositions comprising acetylsalicylic acid and a phosphate salt
EP3501523A1 (en) 2017-12-22 2019-06-26 Asamedic AS Two-component compositions comprising acetyl salicylic acid and a carbonate salt
KR20210156389A (ko) 2020-06-17 2021-12-27 재단법인대구경북과학기술원 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002014A1 (en) * 1999-07-02 2001-01-11 Hisamitsu Pharmaceutical Co., Inc. Medicinal compositions for treating colorectal cancer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
JP2009514921A (ja) * 2005-11-10 2009-04-09 バイエル・ヘルスケア・アクチェンゲゼルシャフト 糖尿病性神経障害を処置するためのジアリールウレア
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
GB201002530D0 (en) * 2010-02-15 2010-03-31 Univ Wolverhampton The Di-aspirin derivatives
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida

Also Published As

Publication number Publication date
HK1214169A1 (zh) 2016-07-22
EP2900269A1 (en) 2015-08-05
US20150202214A1 (en) 2015-07-23
AU2013322854A1 (en) 2015-04-02
PH12015500587A1 (en) 2015-05-11
HUE039878T2 (hu) 2019-02-28
KR102210575B1 (ko) 2021-02-02
WO2014048881A1 (en) 2014-04-03
ZA201502840B (en) 2017-11-29
MY183969A (en) 2021-03-17
EP2900269B1 (en) 2018-08-01
US10898500B2 (en) 2021-01-26
BR112015006686A2 (pt) 2019-08-27
AU2013322854B2 (en) 2018-07-19
CL2015000744A1 (es) 2016-01-08
SI2900269T1 (sl) 2018-10-30
CY1120939T1 (el) 2019-12-11
MX2015003728A (es) 2015-09-23
IL237690A0 (en) 2015-05-31
PL2900269T3 (pl) 2019-02-28
CA2885688C (en) 2021-03-02
CA2885688A1 (en) 2014-04-03
ES2687985T3 (es) 2018-10-30
JP6294888B2 (ja) 2018-03-14
SG11201501963RA (en) 2015-04-29
SG10201702356VA (en) 2017-04-27
CN104994876A (zh) 2015-10-21
DK2900269T3 (en) 2018-10-01
KR20150060869A (ko) 2015-06-03
BR112015006686B1 (pt) 2022-04-05
MX357035B (es) 2018-06-25
JP2015529234A (ja) 2015-10-05
EA201500365A1 (ru) 2015-08-31
EA032023B1 (ru) 2019-03-29
PT2900269T (pt) 2018-10-22
LT2900269T (lt) 2018-11-12
RS57875B1 (sr) 2018-12-31
NZ705860A (en) 2018-07-27
IL237690B (en) 2019-07-31

Similar Documents

Publication Publication Date Title
IL289300A (en) Combination therapy for treating cancer
ZA201502840B (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
PT2919796T (pt) Utilização de akkermansia para o tratamento de distúrbios metabólicos
IL225471B (en) Compositions for the prevention and treatment of cancer
PL3296319T3 (pl) Sposoby leczenia nowotworu jelita grubego
IL239007B (en) Eribulin for use in the treatment of breast cancer
HUE048876T2 (hu) Rákos megbetegedések kezelése
HUE036583T2 (hu) Notch jelzõ folyamat inhibitorai és alkalmazásuk rákok kezelésében
PL2739153T3 (pl) Leczenie raka sutka
PT2768493T (pt) Fitocanabinoides para utilização no tratamento do cancro da mama
HUE043171T2 (hu) Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
HUE046667T2 (hu) Rák kombinatív kezelése
IL251083B (en) Compounds and compositions for the treatment of cancer
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
HRP20190046T1 (hr) Kombinirana terapija za liječenje raka
IL238177A0 (en) Methods and preparations for the treatment of cancer
EP3967315C0 (en) AKKERMANSIA MUCINIPHILA FOR THE TREATMENT OF CANCER
PL2914261T3 (pl) Śmiertelność syntetyczna i leczenie nowotworu
EP2830633A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
LT2914254T (lt) Kombinacinės terapijos chemoresistencinių vėžių gydymui
DK3434276T3 (da) Fremgangsmåde og farmaceutisk sammensætning til anvendelse i behandlingen af kræft
HUE045445T2 (hu) Kombinált terápia petefészekrák kezelésére
IL234606B (en) Novel methods and composition for treatment of disease
PL2742356T3 (pl) Środki prognostyczne w leczeniu nowotworów
SI2892925T1 (sl) Kombinacijsko zdravljenje raka